Form 4: Acurx Pharmaceuticals CEO David P. Luci Acquires Shares and Warrants in Direct Offering

David P. Luci, CEO of Acurx Pharmaceuticals, purchased 49,261 shares of common stock and warrants in a registered direct offering and concurrent private placement.

Summary

• On January 6, 2025, David P. Luci, the President and CEO of Acurx Pharmaceuticals, acquired 49,261 shares of common stock at a price of $1.015 per share.
• The acquisition was part of a registered direct offering by Acurx Pharmaceuticals, Inc.
• Luci also acquired warrants for 49,261 shares of common stock at a price of $0 in a concurrent private placement.
• These warrants have an exercise price of $0.9, are exercisable from January 7, 2025, and expire on January 7, 2030.
• Following these transactions, Luci directly owns 1,097,458 shares of common stock.
• Additionally, Luci indirectly owns 15,083 shares through his spouse and 35,000 shares through his child.

Sentiment

Score: 7

Explanation: The CEO's purchase of shares and warrants is generally a positive signal, suggesting confidence in the company's future. However, the document itself is simply a regulatory filing, so the sentiment is moderately positive.

Positives

• The CEO's purchase of shares and warrants may signal confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's prospects. Purchases by executives are often seen as a positive sign.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive sign.
• The capital raise could impact the company's financial flexibility.

Key Dates